Welcome to Scrip
Create an account to read this article
Already a subscriber?
Sanofi Aventis Maps Out India R&D Strategy To Broaden Reach Into Untapped Markets
MUMBAI - For the last five years, the Indian affiliate of French drug giant Sanofi Aventis has been working very quietly, assiduously integrating the operations of the two companies that turned into a single entity as part of a mega-deal in 2004 and then drawing up its rollout program under the newly christened identity
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.
• By
Bayer continues to keep faith in its pharmaceuticals business despite a plethora of problems for the wider group with job cuts, continued debt concerns and ongoing glyphosate litigation claims.
• By
Shares of the Palo Alta, CA-based firm fell as Attruby sales missed elevated investor expectations in the second full quarter since its launch.